Veliflapon

Summary

Veliflapon (CHEMBL88712) is a phase-3 clinical-stage small molecule; indicated across 1 condition including acute coronary syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 361.4 Da · C23H23NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL88712
Name	Veliflapon
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	123723
Molecular formula	C23H23NO3
Molecular weight	361.4
InChIKey	ZEYYDOLCHFETHQ-JOCHJYFZSA-N

SMILES: C1CCC(C1)[C@H](C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O

IUPAC name: (2R)-2-cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]acetic acid

Also known as: BAY X 1005, BAY X-1005, BAY-X-005, BAY-X-1005, DG-031, Veliflapon, VELIFLAPON, veliflapon

Patent coverage: 177 distinct patent families (637 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 574 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Protein deacetylase HDAC6, Polyunsaturated fatty acid 5-lipoxygenase.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ALOX5	7.22	IC50	60	nM	CHEMBL_ACT_1078999
ALOX5	6.66	IC50	220	nM	CHEMBL_ACT_25039634
HDAC6	6.18	IC50	655.8	nM	CHEMBL_ACT_23141019

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute coronary syndrome	3	MONDO:0005542	EFO:0005672

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00353067	PHASE3	SUSPENDED	Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).